192 related articles for article (PubMed ID: 30393846)
41. No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting.
Jacob F; Meier M; Caduff R; Goldstein D; Pochechueva T; Hacker N; Fink D; Heinzelmann-Schwarz V
Gynecol Oncol; 2011 Jun; 121(3):487-91. PubMed ID: 21420727
[TBL] [Abstract][Full Text] [Related]
42. Diagnostic markers for the detection of ovarian cancer in BRCA1 mutation carriers.
Gschwantler-Kaulich D; Weingartshofer S; Rappaport-Fürhauser C; Zeillinger R; Pils D; Muhr D; Braicu EI; Kastner MT; Tan YY; Semmler L; Sehouli J; Singer CF
PLoS One; 2017; 12(12):e0189641. PubMed ID: 29244844
[TBL] [Abstract][Full Text] [Related]
43. The generally low sensitivity of CA 125 for FIGO stage I ovarian cancer diagnosis increases for endometrioid histotype.
Grandi G; Perrone AM; Toss A; Vitagliano A; Friso S; Facchinetti F; Cortesi L; Cascinu S; De Iaco P
Minerva Med; 2020 Apr; 111(2):133-140. PubMed ID: 32338842
[TBL] [Abstract][Full Text] [Related]
44. Estimating the risk of malignancy of adnexal masses: validation of the ADNEX model in the hands of nonexpert ultrasonographers in a gynaecological oncology centre in China.
He P; Wang JJ; Duan W; Song C; Yang Y; Wu QQ
J Ovarian Res; 2021 Dec; 14(1):169. PubMed ID: 34857005
[TBL] [Abstract][Full Text] [Related]
45. Serum human epididymal protein 4 (HE4) as biomarker for the differentiation between epithelial ovarian cancer and ovarian metastases of gastrointestinal origin.
Stiekema A; Boldingh QJ; Korse CM; van der Noort V; Boot H; van Driel WJ; Kenter GG; Lok CA
Gynecol Oncol; 2015 Mar; 136(3):562-6. PubMed ID: 25560808
[TBL] [Abstract][Full Text] [Related]
46. Using a panel of multiple tumor-associated antigens to enhance the autoantibody detection in the immunodiagnosis of ovarian cancer.
Wang P; Qin J; Ye H; Li L; Wang X; Zhang J
J Cell Biochem; 2019 Mar; 120(3):3091-3100. PubMed ID: 30484895
[TBL] [Abstract][Full Text] [Related]
47. Role of osteopontin in differential diagnosis of ovarian tumors.
Moszynski R; Szubert S; Szpurek D; Michalak S; Sajdak S
J Obstet Gynaecol Res; 2013 Nov; 39(11):1518-25. PubMed ID: 23875677
[TBL] [Abstract][Full Text] [Related]
48. A novel diagnostic index combining HE4, CA125 and age may improve triage of women with suspected ovarian cancer - An international multicenter study in women with an ovarian mass.
Karlsen MA; Høgdall EV; Christensen IJ; Borgfeldt C; Kalapotharakos G; Zdrazilova-Dubska L; Chovanec J; Lok CA; Stiekema A; Mutz-Dehbalaie I; Rosenthal AN; Moore EK; Schodin BA; Sumpaico WW; Sundfeldt K; Kristjansdottir B; Zapardiel I; Høgdall CK
Gynecol Oncol; 2015 Sep; 138(3):640-6. PubMed ID: 26086566
[TBL] [Abstract][Full Text] [Related]
49. Diagnostic Model of Serum miR-193a-5p, HE4 and CA125 Improves the Diagnostic Efficacy of Epithelium Ovarian Cancer.
Ren X; Zhang H; Cong H; Wang X; Ni H; Shen X; Ju S
Pathol Oncol Res; 2018 Oct; 24(4):739-744. PubMed ID: 29520570
[TBL] [Abstract][Full Text] [Related]
50. Evaluation of osteopontin and CA125 in detection of epithelial ovarian carcinoma.
Milivojevic M; Boskovic V; Atanackovic J; Milicevic S; Razic S; Kotlica BK
Eur J Gynaecol Oncol; 2013; 34(1):83-5. PubMed ID: 23590008
[TBL] [Abstract][Full Text] [Related]
51. Are serum HE4 or ROMA scores useful to experienced examiners for improving characterization of adnexal masses after transvaginal ultrasonography?
Kaijser J; Van Gorp T; Smet ME; Van Holsbeke C; Sayasneh A; Epstein E; Bourne T; Vergote I; Van Calster B; Timmerman D
Ultrasound Obstet Gynecol; 2014 Jan; 43(1):89-97. PubMed ID: 23828371
[TBL] [Abstract][Full Text] [Related]
52. CA125 and HE4: Measurement Tools for Ovarian Cancer.
Zhao T; Hu W
Gynecol Obstet Invest; 2016; 81(5):430-5. PubMed ID: 27160726
[TBL] [Abstract][Full Text] [Related]
53. A comparison between an ultrasound based prediction model (LR2) and the risk of ovarian malignancy algorithm (ROMA) to assess the risk of malignancy in women with an adnexal mass.
Kaijser J; Van Gorp T; Van Hoorde K; Van Holsbeke C; Sayasneh A; Vergote I; Bourne T; Timmerman D; Van Calster B
Gynecol Oncol; 2013 May; 129(2):377-83. PubMed ID: 23360924
[TBL] [Abstract][Full Text] [Related]
54. MMP3 in Comparison to CA 125, HE4 and the ROMA Algorithm in Differentiation of Ovarian Tumors.
Cymbaluk-Ploska A; Chudecka-Glaz A; Surowiec A; Pius-Sadowska E; Machalinski B; Menkiszak J
Asian Pac J Cancer Prev; 2016; 17(5):2597-603. PubMed ID: 27268637
[TBL] [Abstract][Full Text] [Related]
55. Ultrasonographic markers and preoperative CA-125 to distinguish between borderline ovarian tumors and stage I ovarian cancer.
Zacharakis D; Thomakos N; Biliatis I; Rodolakis A; Simou M; Daskalakis G; Bamias A; Antsaklis A
Acta Obstet Gynecol Scand; 2013 Mar; 92(3):285-92. PubMed ID: 23193945
[TBL] [Abstract][Full Text] [Related]
56. Comparison of candidate serologic markers for type I and type II ovarian cancer.
Lu D; Kuhn E; Bristow RE; Giuntoli RL; Kjær SK; Shih IeM; Roden RB
Gynecol Oncol; 2011 Sep; 122(3):560-6. PubMed ID: 21704359
[TBL] [Abstract][Full Text] [Related]
57. A Biomarker Panel Increases the Diagnostic Performance for Epithelial Ovarian Cancer Type I and II in Young Women.
Leandersson P; Kalapotharakos G; Henic E; Borgfeldt H; Petzold M; Høyer-Hansen G; Borgfeldt C
Anticancer Res; 2016 Mar; 36(3):957-65. PubMed ID: 26976984
[TBL] [Abstract][Full Text] [Related]
58. Diagnostic performance and establishment of reference limits of HE4 in Korean healthy women.
Yu S; Lee JK; Kim JH; Park H; Lee MY; Ryu S; Kwon MJ; Woo HY
Gynecol Oncol; 2016 Oct; 143(1):128-134. PubMed ID: 27426308
[TBL] [Abstract][Full Text] [Related]
59. Diagnostic value of HE4 for ovarian cancer: a meta-analysis.
Yu S; Yang HJ; Xie SQ; Bao YX
Clin Chem Lab Med; 2012 Feb; 50(8):1439-46. PubMed ID: 22868811
[TBL] [Abstract][Full Text] [Related]
60. HE4 in the differential diagnosis of ovarian masses.
Granato T; Porpora MG; Longo F; Angeloni A; Manganaro L; Anastasi E
Clin Chim Acta; 2015 Jun; 446():147-55. PubMed ID: 25892674
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]